



## Dignitana Announces the Outcome of the Rights and Directed Issues

In a press release on 21 December the outcome of the Rights and Directed Issues were announced.

The subscription period for Dignitana AB's ("Dignitana" or "the Company") rights issue with preferential right for the Company's shareholders ended on 18 December 2018.

- The rights issue was covered by subscription commitments and guarantees up to 100 percent of the total amount in the Issue, corresponding to approximately SEK 24.3M.
- 5,383,686 shares, corresponding to 93 percent of the rights issue, was subscribed for with subscription rights and 408,917 shares, corresponding to approximately 7 percent of the rights issue, was subscribed for without subscription rights.
- In total, 1,517,201 shares were subscribed for without subscription right, implying that the rights issue was subscribed for to approximately 119 percent and the Company will receive approximately SEK 24.3M before issue costs.
- There will be no need to utilize the guarantee obligations that have been provided.

Allotment of shares subscribed for without subscription rights has been carried out in accordance with the principles set out in the Information Memorandum prepared for the rights issue and published on 3 December 2018. Notification of allotment of shares subscribed for without subscription rights will be sent shortly to those who were granted shares.

In connection with the rights issue, the Company also decided on three directed issues which were fully subscribed. Two directed rights issues amounting to in total approximately SEK 8.1M comprising 1,920,500 shares and one directed off-setting issue amounting to approximately SEK 1.4M comprising in total 337,828 shares. The directed off-setting issue is to off-set the guarantee fee to guarantors in the rights issue.

Through the rights and directed issues, Dignitana's share capital will increase by SEK 8,050,931 to SEK 48,599,155. The number of shares will increase by 8,050,931 to 48,599,155 shares. When the rights issue is registered, BTA will be converted to shares. The new shares are expected to be traded on Nasdaq First North starting in the middle of January 2019.

Redeye AB (redeye.se) is financial advisor and Advokatfirman Delphi is legal advisor in the preferential rights issue, the directed rights issue and the directed off-setting issue. Aktieinvest is the Company's issuing agent in the issues.

## Dignitana Partners with ThermoTek to Develop Next Generation in Scalp Cooling

On 19 December Dignitana announced details regarding the development and production of DigniCap Delta.

Dignitana AB has partnered with [ThermoTek, Inc.](#) to develop the DigniCap Delta, an advanced model of the 2015 FDA-cleared DigniCap Scalp Cooling System, featuring a new single-patient use cap design and a smaller, more streamlined single-patient machine. U.S. Food and Drug Administration clearance for the new device is anticipated in spring 2019.

As contract development and manufacturing partner in the creation of the DigniCap Delta, ThermoTek brings more than twenty-five years of experience as a leader in the medical device industry and has spearheaded award-winning designs for precision thermal management solutions and compression therapies.

*Read the full press release in [English](#) or [Swedish](#)*

## Dignitana To Exhibit at Arab Health Conference

Dignitana and Middle East distribution partner Tesla Medical Solutions will exhibit The DigniCap Scalp Cooling System at [Arab Health](#) in Dubai January 28 – 31.

Dignitana and Tesla are in booth H1.B72 in the popular USA Pavilion.

Arab Health is the leading healthcare business platform in the Middle East region connecting over 84,000 attendees with service providers offering the latest innovations in healthcare.

## 2018 Year End Report

The 2018 Year End Report will be published 26 February 2019.

## DigniCap in the United States

DigniCap is [available](#) in 27 states, with 117 locations in the U.S. representing 149 machines.

New customers in the past month include:

- Contra Costa Oncology - Walnut Creek, California
- Callahan Cancer Center - North Platte, Nebraska

## Investor Relations Communication

- The email address for investor relations is [investorrelations@dignitana.com](mailto:investorrelations@dignitana.com).
- Per MAR guidelines, inside information will be posted at [www.dignitana.se](http://www.dignitana.se) and distributed to Nasdaq OMX, First North Stockholm, Nordic News Agencies, EU Transparency, and financial websites.
- [Subscribe here](#) to receive this newsletter by email.
- Dignitana AB press releases are posted at <https://investor.dignitana.com/news/>.